Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
59
PYPD Quote, Financials, Valuation and Earnings
Last price:
$3.97
Seasonality move
:
0.75%
Day range:
$3.87 - $3.98
52-week range:
$2.30 - $4.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.63x
Volume:
113K
Avg. volume:
98.2K
1-year change:
34.58%
Market cap:
$40.5M
Revenue:
--
EPS (TTM):
-$2.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
-- | -$0.52 | -- | -70.5% | $12.25 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | 10.1% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
$3.97 | $12.25 | $40.5M | -- | $0.00 | 0% | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.31 | $3.50 | $4.9M | -- | $0.00 | 0% | 1.75x |
|
CGEN
Compugen Ltd.
|
$1.51 | $6.25 | $141.2M | 55.83x | $0.00 | 0% | 20.17x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$5.17 | $399.00 | $7.9M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
22.01% | 1.547 | 12.76% | 2.49x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PYPD
PolyPid Ltd.
|
-- | -$7.5M | -196.11% | -373.79% | -- | -$8.5M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
PolyPid Ltd. vs. Competitors
-
Which has Higher Returns PYPD or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to PolyPid Ltd.'s net margin of --. PolyPid Ltd.'s return on equity of -373.79% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.37 $19.7M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About PYPD or CANF?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 208.56%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.50 which suggests that it could grow by 1018.21%. Given that Can-Fite BioPharma Ltd. has higher upside potential than PolyPid Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is PYPD or CANF More Risky?
PolyPid Ltd. has a beta of 1.489, which suggesting that the stock is 48.89% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock PYPD or CANF?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or CANF?
PolyPid Ltd. quarterly revenues are --, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. PolyPid Ltd.'s net income of -$7.5M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 1.75x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$7.5M CANFCan-Fite BioPharma Ltd.1.75x -- -- --
-
Which has Higher Returns PYPD or CGEN?
Compugen Ltd. has a net margin of -- compared to PolyPid Ltd.'s net margin of -369.06%. PolyPid Ltd.'s return on equity of -373.79% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.37 $19.7M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About PYPD or CGEN?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 208.56%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 313.91%. Given that Compugen Ltd. has higher upside potential than PolyPid Ltd., analysts believe Compugen Ltd. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 CGENCompugen Ltd.4 0 0 -
Is PYPD or CGEN More Risky?
PolyPid Ltd. has a beta of 1.489, which suggesting that the stock is 48.89% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock PYPD or CGEN?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or CGEN?
PolyPid Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. PolyPid Ltd.'s net income of -$7.5M is lower than Compugen Ltd.'s net income of -$7M. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus 20.17x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$7.5M CGENCompugen Ltd.20.17x 55.83x $1.9M -$7M
-
Which has Higher Returns PYPD or NSRX?
Nasus Pharma has a net margin of -- compared to PolyPid Ltd.'s net margin of --. PolyPid Ltd.'s return on equity of -373.79% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.37 $19.7M NSRXNasus Pharma-- -- -- -
What do Analysts Say About PYPD or NSRX?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 208.56%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that PolyPid Ltd. has higher upside potential than Nasus Pharma, analysts believe PolyPid Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 NSRXNasus Pharma0 0 0 -
Is PYPD or NSRX More Risky?
PolyPid Ltd. has a beta of 1.489, which suggesting that the stock is 48.89% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PYPD or NSRX?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or NSRX?
PolyPid Ltd. quarterly revenues are --, which are larger than Nasus Pharma quarterly revenues of --. PolyPid Ltd.'s net income of -$7.5M is higher than Nasus Pharma's net income of --. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$7.5M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns PYPD or PHGE?
BiomX, Inc. has a net margin of -- compared to PolyPid Ltd.'s net margin of --. PolyPid Ltd.'s return on equity of -373.79% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital PYPDPolyPid Ltd.-- -$0.37 $19.7M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About PYPD or PHGE?
PolyPid Ltd. has a consensus price target of $12.25, signalling upside risk potential of 208.56%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 7617.6%. Given that BiomX, Inc. has higher upside potential than PolyPid Ltd., analysts believe BiomX, Inc. is more attractive than PolyPid Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PYPDPolyPid Ltd.3 0 0 PHGEBiomX, Inc.1 0 0 -
Is PYPD or PHGE More Risky?
PolyPid Ltd. has a beta of 1.489, which suggesting that the stock is 48.89% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock PYPD or PHGE?
PolyPid Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PolyPid Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYPD or PHGE?
PolyPid Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. PolyPid Ltd.'s net income of -$7.5M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, PolyPid Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PolyPid Ltd. is -- versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYPDPolyPid Ltd.-- -- -- -$7.5M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 29.72% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 46.38% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.68% over the past day.
